TOLFENAMIC ACID VMD 40 mg/ml - Solution for injection

Authorised

- Tolfenamic acid

Product identification

Medicine name:
TOLFENAMIC ACID VMD 40 mg/ml - Solution for injection

Active substance:
Tolfenamic acid

Target species:
Cattle
Dog
Cat
Pig

Route of administration:
Intramuscular use
Intravenous use
Subcutaneous use

Product details

Active substance and strength:
Tolfenamic acid

40.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Meat and offal. 12 day 12 days
  - Milk. 0 hour 0 hours
  - Meat and offal. 4 day 4 days
  - Milk. 24 hour 24 hours
- **Pig**
  - Meat and offal. 16 day 16 days

Intravenous use:

- **Cattle**
  - Meat and offal. 12 day 12 days
  - Milk. 0 hour 0 hours
  - Meat and offal. 4 day 4 days
  - Milk. 24 hour 24 hours
- **Pig**
  - Meat and offal. 16 day 16 days

Subcutaneous use:

- **Cattle**
  - Meat and offal. 12 day 12 days
  - Milk. 0 hour 0 hours
  - Meat and offal. 4 day 4 days
  - Milk. 24 hour 24 hours
- **Pig**
  - Meat and offal. 16 day 16 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QM01AG02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Valid

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland) , Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland) , Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:vial (glass), Package_size:1 vial, Content:250 ml
Packaging:vial (glass), Package_size:1 vial, Content:25 ml
Packaging:vial (glass), Package_size:1 vial, Content:50 ml
Packaging:vial (glass), Package_size:1 vial, Content:100 ml

Additional information

Entitlement type:
Marketing Authorisation
Marketing Authorisation
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)
Generic application (Article 18 of Regulation (EU) 2019/6)
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
VMD N.V.
VMD N.V.
VMD N.V.

Marketing authorisation date:
3/02/2025
3/02/2025
3/02/2025

Manufacturing sites for batch release:
V.M.D.
Laboratoires Biove

Responsible authority:
European Commission
European Commission
European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:
3/02/2025
3/02/2025
3/02/2025

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 7/05/2025
Download

ema-puar-v6234-tolfenamicacidvmd-initial-en.pdf